All Drug Delivery articles – Page 8
-
ArticleHarnessing natural killer cells to combat age-related diseases
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
-
ArticleLeveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
-
NewsFive HERV expression signatures linked to psychiatric disorders
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
-
ArticleEnhancing gene therapy with Circio
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy. ...
-
ArticleA new era of genetic and mechanistic molecular neuroscience
Neuroscientists are increasingly viewing disorders of the brain through the lens of the underlying molecular mechanisms as sometimes illuminated by genetic variants, rather than classifying disorders based solely on the clinical symptoms. The next step in the evolution of antiseizure medication will likely come from studying these ...
-
NewsMesothelial cells in omental adipose tissue hinder adipogenesis
The discovery that omental fat has a mechanism to limit adipocyte formation may lead to new treatments for obesity and metabolic disease.
-
WhitepaperPoster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
-
NewsNanoparticle targets primary tumours and brain metastases
A specialised drug-loaded nanoparticle, which can cross the blood-brain barrier, shrunk both breast tumours and breast cancer cells.
-
ReportBeyond the lab: cell and gene therapy
Download this report now to access exclusive content on innovative cancer treatments, regenerative medicine, gene therapy, and expert insights from leading professionals in the field.
-
WhitepaperPoster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
-
ArticleBiomarker identification in the realm of rare diseases
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
-
ArticleWomen in Stem with Stefanie Flückiger-Mangual
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich, Switzerland) and holds a PhD in Molecular and Translational Biomedicine from ETH Zurich. She led ...
-
ArticleMachine learning’s growing importance in researching cells
As we move towards more generalised AI models, neural networks and natural language interfaces, we’re starting to see machine learning take the place of higher order reasoning and data analysis “sense making.” Traditional scientific inquiry has typically been about asking specific questions of a specific model system under specific conditions. ...
-
ArticleWomen in Stem with Laura Figulla
Dr Laura Figulla is the CEO of mbiomics. Laura co-founded mbiomics which is dedicated to unlocking the true value of the microbiome by developing next-generation live biotherapeutics (LBPs). Throughout her career, Laura has combined her entrepreneurial spirit with her diverse academic background in business, economics, and medicine to build companies ...
-
News
New findings regarding diabetes risk in childhood cancer survivors
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
-
ArticleOvercoming the complexity of free energy perturbation calculations
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
-
ArticleWomen in Stem with Lidia Pieri
Lidia Pieri earned a Master’s degree with honours in high energy physics at CERN, a PhD in theoretical astroparticle physics from Rome-3 (Italy) and an Executive MBA in Business Innovation with honours from the MIB school in Trieste. During the academic period she gained international exposure and recognition working as ...
-
NewsDrug-loaded 3D printed films could revolutionise liver cancer treatment
The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
-
NewsBlastoids enable greater understanding of human gastrulation
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.
-
NewsEliminating the HIV virus from infected cells with CRISPR-Cas
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.